Gubra ApS
- BID
47.22
- ASK
47.4
- 88 Units510 Units
- 07/22, 21:59:59 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
11.49%
Market Cap
-
P/E Ratio
4.98
Dividend Yield
0.00 %
Earnings per Share
13.94 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 47.24 G | 0 Units |
| PRICE DETERMINATION TIME | 07/22/2026 / 09:56:30 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 47.26 | 45.78 |
| PREV. DAY'S PRICE | 46.82 | (07/21) |
| CHANGE DAY BEFORE | +0.42 | 0.90 % |
| 52 WEEK HIGH / LOW | 74.1 (01/05) | 41.84 (04/30) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -0.39 | -0.30 | 13.94 | -1.69 | -0.24 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | - | 4.98 | - | - |
PRICE - BOOK RATIO | 4.25 | 22.58 | 7.38 | - | - |
PRICE - SALES RATIO | 9.25 | 38.28 | 3.23 | - | - |
PRICE - CASH FLOW RATIO | - | 2,027.01 | 4.97 | - | - |
Master Data
| WKN | A3D9NV |
| ISIN | DK0062266474 |
| SYMBOL | PI3 |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | GUBRA APS DK 1 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 4.56 % | 3.36 % | 5.21 % | -22.23 % | -11.49 % | 290.17 % | - | -32.63 % |
| HIGH | 48.36 | 48.86 | 50.25 | 63.80 | 74.10 | 100.00 | - | 74.10 |
| LOW | 44.76 | 42.16 | 41.84 | 41.84 | 41.84 | 12.00 | - | 41.84 |
Dividende
pro Aktie
GUBRA APS DK 1 does not deliver dividend information
Company profile
Gubra A/S engages in providing research and development services to pharmaceutical and biotechnology companies on a contract basis. It operates through two business segments: Pre-clinical Contract Research (CRO), Discovery and Partnerships (D and P), and Gubra Green. The CRO segment refers to pre-clinical contract research and development services within metabolic and fibrotic diseases. The D and P segment include portfolio strategy in the form of upfront payments, research payments, milestone payments, and royalties. The Gubra Green segment relates to investments in targeting assets. The company was founded by Jacob Jelsing and Niels Vrang in 2008 and is headquartered in Hørsholm, Denmark.
Structured products for Gubra ApS
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.